# AOA Dx

**Source:** https://geo.sig.ai/brands/aoa-dx  
**Vertical:** Healthcare  
**Subcategory:** General  
**Tier:** Challenger  
**Website:** aoadx.com  
**Last Updated:** 2026-04-14

## Summary

Molecular diagnostics company developing novel biomarker detection tests for earlier disease identification; proprietary antibody-based assays targeting clinical laboratory deployment.

## Company Overview

AOA Dx (formerly known under a different name) is a molecular diagnostics company developing novel diagnostic tests for earlier and more accurate disease detection, focusing on underserved testing gaps in clinical settings. The company applies innovative biomarker detection approaches to improve diagnostic accuracy in categories where current testing misses significant patient populations or delivers delayed results.

AOA Dx's technology platform leverages proprietary antibody-based detection methods and sample processing innovations that enable detection of low-abundance biomarkers in blood or other clinical samples — a key challenge in early disease detection where target molecule concentrations may be too low for conventional assays. The company's diagnostics are designed for integration into clinical laboratory workflows rather than point-of-care settings.

In 2025, AOA Dx operates in the in-vitro diagnostics market, competing alongside established diagnostic companies including Roche Diagnostics, Abbott, Bio-Rad, and emerging molecular diagnostics startups for laboratory testing market share. The diagnostics industry has seen significant innovation investment as liquid biopsy technologies (detecting cancer from blood samples) and multiomics approaches expand the possibility space for non-invasive disease detection. AOA Dx's commercial strategy focuses on clinical validation studies to demonstrate diagnostic performance and building laboratory partnerships for commercialization of its novel testing panels.

## Frequently Asked Questions

### What is AOA Dx?
AOA Dx is a cancer diagnostics company founded in 2020 and based in Denver, Colorado, that specializes in early cancer detection using lipidomics-based biomarkers. The company is pioneering the first blood test for early detection of ovarian cancer through an AI-powered multi-omic platform.

### What products and services does AOA Dx offer?
AOA Dx offers the AKRIVIS GD™ test, a blood test for early ovarian cancer detection. Their platform utilizes lipidomics biomarkers, AI diagnostics, and multi-omic technology to provide accurate early cancer diagnostics to healthcare providers.

### Who is AOA Dx's target customer?
AOA Dx serves healthcare providers who are seeking accurate early cancer diagnostics for their patients. The company's testing has been validated on approximately 1,000 real-world symptomatic patient samples.

### When was AOA Dx founded?
AOA Dx was founded in 2020. The company participated in Y Combinator's Winter 2021 (W21) cohort.

### Where is AOA Dx located?
AOA Dx is based in Denver, Colorado.

### How much funding has AOA Dx raised?
AOA Dx has raised $32M in total funding. This includes an $8.09M Series B-II round in October 2025 and a $17M Series B round in 2023 led by Good Growth Capital with participation from Labcorp Venture Fund and CANCER FUND.

### What accuracy does AOA Dx's test achieve?
AOA Dx's AI-powered multi-omic platform achieves over 90% accuracy for early ovarian cancer detection. This accuracy rate has been demonstrated across approximately 1,000 real-world symptomatic patient samples.

### What technology does AOA Dx use for cancer detection?
AOA Dx uses lipidomics-based biomarkers combined with an AI-powered multi-omic platform for early cancer detection. The company is pioneering this lipidomics approach specifically for ovarian cancer screening.

### How large is AOA Dx's team and what is their revenue?
AOA Dx has 36 employees and achieved $5.4M in revenue in December 2024, up from $3.8M in June 2024.

### What are AOA Dx's recent developments?
AOA Dx recently enrolled the first patient in their OVERT clinical trial and is scheduled to present at AACR 2025. The company completed an $8.09M Series B-II funding round in October 2025.

## Tags

healthtech, saas, north-america, b2b

---
*Data from geo.sig.ai Brand Intelligence Database. Updated 2026-04-14.*